Kessler Paul D. 4
4 · NABI BIOPHARMACEUTICALS · Filed Apr 5, 2011
Insider Transaction Report
Form 4
Kessler Paul D.
SVP Clinical, Med. & Reg.; CMO
Transactions
- Sale
Common Stock
2011-04-05$5.76/sh−8,596$49,479→ 122,671 total - Award
Common Stock
2011-04-01+36,000→ 131,267 total - Award
Stock Option (right to buy)
2011-04-01+90,000→ 90,000 totalExercise: $5.81Exp: 2018-04-01→ Common Stock (90,000 underlying)
Footnotes (3)
- [F1]Restricted Stock which vests in four equal annual installments beginning on April 1, 2012.
- [F2]This disposition was made to fund the Reporting Person's tax obligation arising from the vesting of restricted stock.
- [F3]This Option will become exercisable in four equal annual installments beginning on April 1, 2012.